Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy.
Dendritic cell vaccination has been applied to the treatment of a variety of cancers, including malignant astrocytoma. We have treated 13 patients with malignant astrocytoma using dendritic cell vaccination and have shown that this treatment is safe and is likely to be effective in combination with standard adjuvant therapy. Future studies should prospectively incorporate dendritic cell vaccination together with chemotherapy. Ideally, dendritic cell vaccination should be tested in a prospective fashion, in a coordinated trial involving multiple centres.
Walker
David G
DG
Department of Neurosurgery, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia. dwalker@brizbrain.com.au
Laherty
Richard
R
Tomlinson
Frank H
FH
Chuah
Teong
T
Schmidt
Chris
C
D000328:Adult; D000368:Aged; D001254:Astrocytoma / Q000473:pathology / Q000628:therapy*; D001932:Brain Neoplasms / Q000473:pathology / Q000628:therapy*; D016827:CD8 Antigens / Q000378:metabolism; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant / Q000379:methods*; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods*; D017493:Leukocyte Common Antigens / Q000378:metabolism; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
D016827:CD8 Antigens; D019496:Cancer Vaccines; D017493:Leukocyte Common Antigens